Class 3 recall- Fingolimod Glenmark 0.5 mg Hard Capsules

CLASS 3 RECALL

PLEASE READ AND CONFIRM THAT YOU HAVE RECEIVED THIS.

We have received a Class 3 Recall from Glenmark Pharmaceuticals Europe Limited on FINGOLIMOD CAP 0.5MG

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-glenmark-pharmaceuticals-europe-limited-fingolimod-glenmark-0-dot-5-mg-hard-capsules-el-26-a-slash-02?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=53be9484-a57c-41df-9fe0-10338d61497b&utm_content=immediately

MHRA ref: DMRC-38142990

Reason: Glenmark Pharmaceuticals Europe Limited is recalling the above batch after stability testing showed out-of-specification results. The batch is being recalled as a precautionary measure following test results that showed a delay in capsule dissolution.

Please can you ensure that your stores quarantine the product listed below.

Further Information

For all medical information enquiries and information on this product, medical_information@glenmarkpharma.com or telephone 0044 8004 580 383

For stock control enquiries please email orders.uk@glenmarkpharma.com

Please return all affected stock to your original supplier for credit. As Alliance Healthcare has not supplied the affected batch, we will not be accepting returns.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 recall-Paliperidone PR pre-filled syringe 50, 75, 100 & 150mg

Mercury Pharmaceuticals Ltd is recalling remaining stock of paliperidone pre-filled syringes as a precautionary measure due to Good Manufacturing Practice (GMP) deficiencies cited during a recent inspection at the finished product manufacturing site.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-mercury-pharmaceuticals-ltd-paliperidone-mercury-pharma-prolonged-release-suspension-for-injection-in-pre-filled-syringes-el-26-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e99da014-d03f-4b15-9aee-619b70601394&utm_content=immediately

MHRA drug alert date: 20/01/26

Further Information

For stock enquiries please contact Advanz Pharma Customer Care Services on +44 (0) 208 588 9441 or email customercare@advanzpharma.com

For medical information enquiries please contact Advanz Pharma Medical Information on +44 (0) 208 588 9131 or email medicalinformation@advanzpharma.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Nestle SMA Infant Milk - Food Standards Agency Consumer Recall Notice

Retailers of these products must display the recall notice from Nestle which can be found using this link.

Product recall date: 06/01/26

Nestlé recalls several SMA Infant Formula and Follow-On Formula as a precaution because of the possible presence of cereulide (toxin) | Food Standards Agency

Company led recall-Nestle Multiple

Nestle have detected a quality defect in an ingredient from a supplier

Product recall date 06/01/26

Further Information

https://www.nestle.co.uk/en-gb/getintouch

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Company led recall- SMA Alfamino

Nestle have detected a quality defect in an ingredient from a supplier

Product recall date 06/01/26

Further Information

https://www.nestle.co.uk/en-gb/getintouch

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall-Prednisolone 5mg soluble tabs

Activase Pharmaceuticals Limited is recalling two batches of Prednisolone 5mg Soluble Tablets as a precautionary measure due to a limited number of reports of blister pockets becoming swollen over time.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-activase-pharmaceuticals-limited-prednisolone-5mg-soluble-tablets-el-25-a-slash-54?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1366bdc1-73bc-4d3f-b72b-aa21c0cdac67&utm_content=immediately

MHRA drug alert date 15/12/25

Further Information

For all medical information enquiries and information on this product, please email eupvg@genreg.eu or telephone 020 72010421.

For stock control enquiries please email info@genesis-pharma.com or telephone 0207 2010400.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 recall-Pharma Ltd, Clarithromycin 500 mg powder for concentrate for solution for infusion

Hameln Pharma Ltd is recalling the batches of Clarithromycin 500 mg powder for concentrate for solution for infusion listed in the table. Following an inspection of the clarithromycin lactobionate raw material manufacturer, the certification of suitability for use in medicines was withdrawn due to non-compliance with Good Manufacturing Practice.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-hameln-pharma-ltd-clarithromycin-500-mg-powder-for-concentrate-for-solution-for-infusion-el-25-a-slash-53?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=a7aee035-dcbb-4a49-acb7-05dc0d52d0d7&utm_content=immediately

MHRA drug alert date: 11/12/25

Further Information

For all medical information enquiries and information on this product, please email drug.safety@hameln-pharma.co.uk or telephone +44 (0)1452 621 661.

For stock control enquiries please email customer.services@hameln-pharma.co.uk , or telephone +44 (0)1452 621 661.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 Caution In Use-Amitriptyline Hydrochloride 10mg, 25mg, 50mg Tablets Flamingo Pharma

Flamingo Pharma UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.

MHRA drug alert Date: 10/12/25

MHRA drug alert link Class 4 Medicines Defect Notification: Flamingo Pharma UK Ltd, Amitriptyline Hydrochloride 10mg, 25mg, 50mg Tablets, EL(25)A/52 - GOV.UK

This is a caution in use only we are not accepting stock returns

further information

For all medical information enquiries and information on this product, please email safety@flamingopharma.co.uk , or telephone +44 (0) 800 0668 348.

For stock control enquiries please email sales@flamingopharma.co.uk , or telephone +44 (0) 7784 240228.

Field safety notice-Stomahesive seal 48mm

This communication is to inform customers that Convatec is issuing a voluntary Field Correction Notice due to a
formatting discrepancy identified in the UDI barcode printed on the packaging of the products listed.

The barcode encoding on the secondary Market unit (sellable unit) places the Production Identifier (PI) before the
Device Identifier (DI), contrary to the expected UDI structure. This formatting may prevent the barcode from being
scanned correctly by some customer systems. The human-readable UDI text on the secondary Market unit (sellable
unit) remains accurate and complete. Note that the labelling on the products inside is also correct.

This is a caution in use only we are not accepting stock returns

further information

uk.customerservice@convatec.com

Class 4 caution in use- Baclofen 10mg Tablets, Special Concept Development UK Limited

Special Concept Development UK Limited has informed the MHRA that the Patient Information Leaflet (PIL) for the batches listed in this notification do not contain the correct safety information.

MHRA drug alert Date: 27/11/25

MHRA drug alert link:Class 4 Medicines Defect Notification: Special Concept Development UK Limited, Baclofen 10mg Tablets, EL(25)A/51 - GOV.UK

This is a caution in use only we are not accepting stock returns

further information

For medical information enquiries please email medinfo@rxfarma.co.uk or telephone 08003580163.

For supply chain inquiries please contact email supplychain@rxfarma.co.uk or telephone 01923 332 777.